Revolution Medicines, Inc. Capital Expenditures
Revolution Medicines, Inc. (RVMD) reported Capital Expenditures of $3.82 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-05
- Revolution Medicines, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $2.29M, a 69.32% decline year-over-year.
- Revolution Medicines, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $1.54M, a 52.91% decline year-over-year.
- Revolution Medicines, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $1.93M, a 57.53% increase year-over-year.
- Revolution Medicines, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $3.35M, a 4.86% decline year-over-year.
- Revolution Medicines, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $15.99M, a 55.12% increase from fiscal 2024.
- Revolution Medicines, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $10.31M, a 33.37% increase from fiscal 2023.
- Revolution Medicines, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $7.73M, a 28.54% decline from fiscal 2022.
- Revolution Medicines, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $10.82M, a 65.69% increase from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $3.82M 10-Q · filed 2026-08-05 | $5.75M derived: sum of 3 quarters · filed 2026-08-05 | $9.10M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $1.54M 10-Q · filed 2026-05-06 | $3.46M derived: sum of 2 quarters · filed 2026-05-06 | $6.81M derived: sum of 3 quarters · filed 2026-05-06 | $14.26M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $5.27M derived: sum of 2 quarters · filed 2026-02-25 | $12.72M derived: sum of 3 quarters · filed 2026-08-05 | $15.99M 10-K · filed 2026-02-25 |
| 2025-09-30 | $3.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $10.80M derived: sum of 2 quarters · filed 2026-08-05 | $14.06M 10-Q · filed 2025-11-05 | $15.29M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $7.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $10.72M 10-Q · filed 2026-08-05 | $11.94M derived: sum of 3 quarters · filed 2026-08-05 | $15.46M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $3.27M 10-Q · filed 2026-05-06 | $4.49M derived: sum of 2 quarters · filed 2026-05-06 | $8.01M derived: sum of 3 quarters · filed 2026-05-06 | $10.41M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $4.74M derived: sum of 2 quarters · filed 2026-02-25 | $7.14M derived: sum of 3 quarters · filed 2026-02-25 | $10.31M 10-K · filed 2026-02-25 |
| 2024-09-30 | $3.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $5.92M derived: sum of 2 quarters · filed 2025-11-05 | $9.09M 10-Q · filed 2025-11-05 | $11.40M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $2.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $5.57M 10-Q · filed 2025-08-06 | $7.88M derived: sum of 3 quarters · filed 2026-02-25 | $10.42M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $3.17M 10-Q · filed 2025-05-07 | $5.48M derived: sum of 2 quarters · filed 2026-02-25 | $8.02M derived: sum of 3 quarters · filed 2026-02-25 | $9.14M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $2.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $4.85M derived: sum of 2 quarters · filed 2026-02-25 | $5.97M derived: sum of 3 quarters · filed 2026-02-25 | $7.73M 10-K · filed 2026-02-25 |
| 2023-09-30 | $2.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $3.65M derived: sum of 2 quarters · filed 2024-11-06 | $5.41M 10-Q · filed 2024-11-06 | $8.29M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $1.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $2.88M 10-Q · filed 2024-08-07 | $5.75M derived: sum of 3 quarters · filed 2025-02-26 | $9.28M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $1.76M 10-Q · filed 2024-05-08 | $4.63M derived: sum of 2 quarters · filed 2025-02-26 | $8.16M derived: sum of 3 quarters · filed 2025-02-26 | $10.69M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $2.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $6.40M derived: sum of 2 quarters · filed 2025-02-26 | $8.93M derived: sum of 3 quarters · filed 2025-02-26 | $10.82M 10-K · filed 2025-02-26 |
| 2022-09-30 | $3.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $6.05M derived: sum of 2 quarters · filed 2023-11-06 | $7.94M 10-Q · filed 2023-11-06 | $9.12M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $2.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $4.42M 10-Q · filed 2023-08-08 | $5.60M derived: sum of 3 quarters · filed 2024-02-26 | $6.05M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $1.89M 10-Q · filed 2023-05-08 | $3.07M derived: sum of 2 quarters · filed 2024-02-26 | $3.53M derived: sum of 3 quarters · filed 2024-02-26 | $4.84M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $1.64M derived: sum of 2 quarters · filed 2024-02-26 | $2.95M derived: sum of 3 quarters · filed 2024-02-26 | $6.53M 10-K · filed 2024-02-26 |
| 2021-09-30 | $454.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $1.77M derived: sum of 2 quarters · filed 2022-11-07 | $5.34M 10-Q · filed 2022-11-07 | $6.51M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $1.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $4.89M 10-Q · filed 2022-08-09 | $6.06M derived: sum of 3 quarters · filed 2023-02-27 | $6.75M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $3.58M 10-Q · filed 2022-05-09 | $4.75M derived: sum of 2 quarters · filed 2023-02-27 | $5.43M derived: sum of 3 quarters · filed 2023-02-27 | $5.91M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $1.86M derived: sum of 2 quarters · filed 2023-02-27 | $2.33M derived: sum of 3 quarters · filed 2023-02-27 | $2.93M 10-K · filed 2023-02-27 |
| 2020-09-30 | $687.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $1.16M derived: sum of 2 quarters · filed 2021-11-10 | $1.76M 10-Q · filed 2021-11-10 | $2.27M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $474.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $1.08M 10-Q · filed 2021-08-11 | $1.59M derived: sum of 3 quarters · filed 2022-02-28 | $2.69M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $603.00K 10-Q · filed 2021-05-10 | $1.11M derived: sum of 2 quarters · filed 2022-02-28 | $2.22M derived: sum of 3 quarters · filed 2022-02-28 | $2.85M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $510.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.62M derived: sum of 2 quarters · filed 2022-02-28 | $2.25M derived: sum of 3 quarters · filed 2022-02-28 | $2.59M 10-K · filed 2022-02-28 |
| 2019-09-30 | $1.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $1.74M derived: sum of 2 quarters · filed 2020-11-12 | $2.08M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $631.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $972.00K 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $341.00K 10-Q · filed 2020-05-14 | |||
| 2018-12-31 | $1.50M 10-K · filed 2021-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |